Craft
Equillium

Equillium

Phase III Patients Enrolled

223

FY, 2017

Market Capitalization

$49.4 M

2022-11-23

Equillium Summary

Company summary

Overview
Equillium is a biotechnology company developing products for autoimmune and inflammatory disorders and immuno-inflammation. The Company’s first product candidate, EQ001, is a clinical-stage monoclonal antibody that targets the immune receptor CD6. It plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis.
Type
Public
Status
Active
Founded
2017
HQ
San Diego, CA, US | view all locations
Website
https://equilliumbio.com/
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key people

  • Bruce Steel

    Bruce Steel, Chief Executive Officer

  • Jason Keyes

    Jason Keyes, Chief Financial Officer

    • Daniel Bradbury

      Daniel Bradbury, Executive Chairman

      • Stephen Connelly

        Stephen Connelly, Chief Scientific Officer

      Operating MetricsView all

      Phase III Patients Enrolled

      223

      FY, 2017

      Phase II Patients Enrolled

      110

      FY, 2017

      LocationsView all

      2 locations detected

      • San Diego, CA HQ

        United States

        2223 Avenida De La Playa #108, La Jolla

      • South San Francisco, CA

        United States

        601 Gateway Blvd #1020

      Equillium Financials

      Summary financials

      Net income (Q3, 2022)
      ($13.7M)
      Cash (Q3, 2022)
      $25.7M
      EBIT (Q3, 2022)
      ($13.2M)
      Enterprise value
      $38.0M

      Footer menu